Patients get extended access to promising HAE drug in 10-Year safety study
NCT ID NCT04933721
Summary
This study provides continued access to the oral medication berotralstat for people with hereditary angioedema (HAE) who were in previous trials. It aims to monitor the long-term safety and tolerability of the drug for up to 10 years in adults and adolescents, and up to 5 years in children. The study is for patients in countries where the drug is not yet commercially available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study Center
Ottawa, Canada
-
Study Center
Brno, Czechia
-
Study Center
Pilsen, Czechia
-
Study Center
Grenoble, France
-
Study Center
Marseille, France
-
Study Center
Paris, France
-
Study Center
Frankfurt, Germany
-
Study Center
Skopje, North Macedonia
-
Study Center
Krakow, Poland
-
Study Center
Martin, Slovakia
-
Study Center
Cape Town, South Africa
-
Study Center
Daegu, South Korea
-
Study Center
Gwangju, South Korea
-
Study Center
Seoul, South Korea
-
Study Center
Madrid, Spain
-
Study Center
Bristol, United Kingdom
Conditions
Explore the condition pages connected to this study.